Cargando…

Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support

Patients receiving durable mechanical circulatory support (MCS) require life-long anticoagulation with a vitamin K antagonist (VKA). Due to alternations in hemostasis, concomitant therapy with antiplatelet agents and critical illness, they are at increased risk of thromboembolic and bleeding complic...

Descripción completa

Detalles Bibliográficos
Autores principales: Levesque, Amy A., Lewin, Andrea R., Rimsans, Jessica, Sylvester, Katelyn W., Coakley, Lara, Melanson, Frank, Mallidi, Hari, Mehra, Mandeep, Givertz, Michael M., Connors, Jean M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714942/
https://www.ncbi.nlm.nih.gov/pubmed/30907120
http://dx.doi.org/10.1177/1076029619837362
_version_ 1783447150868299776
author Levesque, Amy A.
Lewin, Andrea R.
Rimsans, Jessica
Sylvester, Katelyn W.
Coakley, Lara
Melanson, Frank
Mallidi, Hari
Mehra, Mandeep
Givertz, Michael M.
Connors, Jean M.
author_facet Levesque, Amy A.
Lewin, Andrea R.
Rimsans, Jessica
Sylvester, Katelyn W.
Coakley, Lara
Melanson, Frank
Mallidi, Hari
Mehra, Mandeep
Givertz, Michael M.
Connors, Jean M.
author_sort Levesque, Amy A.
collection PubMed
description Patients receiving durable mechanical circulatory support (MCS) require life-long anticoagulation with a vitamin K antagonist (VKA). Due to alternations in hemostasis, concomitant therapy with antiplatelet agents and critical illness, they are at increased risk of thromboembolic and bleeding complications compared with the general population managed on VKAs. To prevent thrombotic events, current guidelines recommend that patients with MCS receive long-term anticoagulation with a VKA to maintain a target international normalized ratio (INR) as specified by device manufacturers, but limited data exist regarding specific routine management of anticoagulation therapy and its potential complications. To optimize anticoagulation management and minimize risk in these patients, we have centralized anticoagulation management in a collaborative approach between the inpatient hemostatic and antithrombotic (HAT) stewardship service and between ambulatory anticoagulation management service (AMS) and the advanced heart disease team. Patients are followed by these three services beginning when the device is implanted and extending the duration that patients have the device. The teams include multiple clinicians from cardiac surgery, cardiology, hematology, pharmacy, nursing, case management, nutrition, and psychiatry, therefore, in order to standardize practice among clinicians without compromising patient centered decision making, we assembled an interdisciplinary team to create multiple treatment guidelines. In addition to a centralized and collaborative approach, our guidelines ensure seamless transitions of care between the inpatient and outpatient settings. We believe our approach has demontrated a positive improvement in the care of these challenging patients. In this article, we present our comprehensive centralized anticoagulation management approach for patients with left ventricular assist systems (LVAS).
format Online
Article
Text
id pubmed-6714942
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67149422019-09-04 Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support Levesque, Amy A. Lewin, Andrea R. Rimsans, Jessica Sylvester, Katelyn W. Coakley, Lara Melanson, Frank Mallidi, Hari Mehra, Mandeep Givertz, Michael M. Connors, Jean M. Clin Appl Thromb Hemost Original Article Patients receiving durable mechanical circulatory support (MCS) require life-long anticoagulation with a vitamin K antagonist (VKA). Due to alternations in hemostasis, concomitant therapy with antiplatelet agents and critical illness, they are at increased risk of thromboembolic and bleeding complications compared with the general population managed on VKAs. To prevent thrombotic events, current guidelines recommend that patients with MCS receive long-term anticoagulation with a VKA to maintain a target international normalized ratio (INR) as specified by device manufacturers, but limited data exist regarding specific routine management of anticoagulation therapy and its potential complications. To optimize anticoagulation management and minimize risk in these patients, we have centralized anticoagulation management in a collaborative approach between the inpatient hemostatic and antithrombotic (HAT) stewardship service and between ambulatory anticoagulation management service (AMS) and the advanced heart disease team. Patients are followed by these three services beginning when the device is implanted and extending the duration that patients have the device. The teams include multiple clinicians from cardiac surgery, cardiology, hematology, pharmacy, nursing, case management, nutrition, and psychiatry, therefore, in order to standardize practice among clinicians without compromising patient centered decision making, we assembled an interdisciplinary team to create multiple treatment guidelines. In addition to a centralized and collaborative approach, our guidelines ensure seamless transitions of care between the inpatient and outpatient settings. We believe our approach has demontrated a positive improvement in the care of these challenging patients. In this article, we present our comprehensive centralized anticoagulation management approach for patients with left ventricular assist systems (LVAS). SAGE Publications 2019-03-24 /pmc/articles/PMC6714942/ /pubmed/30907120 http://dx.doi.org/10.1177/1076029619837362 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Levesque, Amy A.
Lewin, Andrea R.
Rimsans, Jessica
Sylvester, Katelyn W.
Coakley, Lara
Melanson, Frank
Mallidi, Hari
Mehra, Mandeep
Givertz, Michael M.
Connors, Jean M.
Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support
title Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support
title_full Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support
title_fullStr Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support
title_full_unstemmed Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support
title_short Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support
title_sort development of multidisciplinary anticoagulation management guidelines for patients receiving durable mechanical circulatory support
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714942/
https://www.ncbi.nlm.nih.gov/pubmed/30907120
http://dx.doi.org/10.1177/1076029619837362
work_keys_str_mv AT levesqueamya developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT lewinandrear developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT rimsansjessica developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT sylvesterkatelynw developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT coakleylara developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT melansonfrank developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT mallidihari developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT mehramandeep developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT givertzmichaelm developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport
AT connorsjeanm developmentofmultidisciplinaryanticoagulationmanagementguidelinesforpatientsreceivingdurablemechanicalcirculatorysupport